


ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK

Karen A. Nahmod and Francisco Vega, The University of Texas MD Anderson Cancer Center



The patient is a 29-year-old male presenting with rapidly enlarging cervical adenopathy and no previous significant clinical history. Histologic sections show a diffuse lymphoma composed of large immunoblasts/plasmablasts (panel A; original magnification $\times 100$, hematoxylin and eosin stain). The neoplastic cells are positive for CD138 (panel B; original magnification $\times 40$), OCT2 (panel C; original magnification $\times 40$), BOB1 (panel D; original magnification $\times 40$), ALK (panel E; original magnification $\times 100$), MUM-1, and EMA and negative for CD45 (panel F; original magnification $\times 100$), CD30, HHV8, EBER, CD19, CD20, CD22, kappa, and lambda. The expression of ALK, with a granular cytoplasmic positivity, supported the diagnosis of ALK⁺ large B-cell lymphoma (ALK⁺ LBCL).

ALK⁺ LBCL is a rare (<200 cases reported) and aggressive lymphoma with a plasmablastic immunophenotype and ALK expression. Other neoplasms showing ALK expression due to ALK gene rearrangements include ALK⁺ histiocytosis, anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors, and non-small cell lung cancers. The immunohistochemical staining pattern of ALK differs depending on the ALK fusion partner. A characteristic granular cytoplasmic pattern is associated with *CLTC::ALK* and *SEC31A::ALK*, whereas a nongranular pattern is associated with *NPM1::ALK*, *SQSTM1::ALK*, *RANBP2::ALK*, and *EML4::ALK* rearrangements. If the partner is *NPM1* (the most frequent partner in ALCL), the staining is both nuclear and cytoplasmic. In ALK⁺ LBCL, some data suggest that a nongranular cytoplasmic pattern is associated with a more aggressive behavior.